Comparison of Clinicopathological Features of Biliary Neuroendocrine Carcinoma with Adenocarcinoma

Masahiro Shiihara, Ryota Higuchi, Toru Furukawa, Takehisa Yazawa, Shuichiro Uemura, Wataru Izumo, Masakazu Yamamoto

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: This study aimed to demonstrate the clinical features and postoperative outcomes of extrahepatic bile duct (EHBD) neuroendocrine carcinoma (NEC) and compared with those of adenocarcinoma. Methods: We retrospectively analyzed patients with EHBD cancer operated in our institution between 1995 and 2015. Results: Of 475 patients, 468 had adenocarcinoma, while 7 had NEC/mixed adenoneuroendocrine carcinoma (MANEC) in this study. There were no notable preoperative and pathological features in patients with NEC/MANEC. However, patients with NEC/MANEC had a higher recurrence rate (51.8 vs. 100%, p = 0.016), poorer relapse-free survival (RFS) time (the median RFS time: 35 vs. 12 months, p = 0.006), and poorer overall survival (OS) time (the median OS time: 60 vs. 19 months, p = 0.078) than those with adenocarcinoma. Furthermore, patients with NEC/MANEC had higher rates of liver metastasis (11.9 vs. 85.7%, p < 0.001) than those with adenocarcinoma. In multivariable regression analysis, pathological type with NEC/MANEC was a risk factor for poorer RFS (p = 0.022, hazard ratio: 6.09). Conclusions: Patients with NEC/MANEC have high malignant potential and poor outcomes. It is necessary to develop an effective approach and postoperative adjuvant treatment for patients with NEC/MANEC.

Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalDigestive Surgery
Volume38
Issue number1
DOIs
Publication statusPublished - 2021 Jan
Externally publishedYes

Keywords

  • Bile duct
  • Mixed adenoneuroendocrine carcinoma
  • Neuroendocrine carcinoma

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Fingerprint Dive into the research topics of 'Comparison of Clinicopathological Features of Biliary Neuroendocrine Carcinoma with Adenocarcinoma'. Together they form a unique fingerprint.

Cite this